Quick Buzz Feed
Doximity reports fiscal Q1 revenue of $156.6 million with strong workflow growth. See how its AI suite and 85% physician reach position the company in expanding digital health markets.
The global market for agentic AI in healthcare is projected for sharp growth, with forecasts indicating an increase from US$1.45 billion in 2025 to US$19.71 billion by 2034. North America currently accounts for over 45% of this segment. Digital health is also seeing rising investment in AI-driven diagnostics and clinical operations. While generative AI applications in clinical trials are expected to expand, some market forecasts for this specific area are viewed by observers as potentially overstated due to materially smaller base figures from other forecasters.
Doximity has a significant market presence, reaching over 85% of U.S. physicians and reporting more than 800,000 unique active workflow providers in its most recent fiscal quarter. Workflow active prescriber growth surged by over 30% year-over-year, and AI Search queries increased by more than 25% quarter-over-quarter. Fiscal first-quarter revenue grew 7% to US$156.6 million, though GAAP net income declined to US$24.3 million. The company raised its full-year fiscal 2027 revenue guidance to a range of US$671 million to US$681 million. Analyst price targets vary widely, from US$18 to US$47, reflecting differing views on growth sustainability and margin pressures. Institutional investors hold nearly 92% of the shares, indicating a stable but concentrated ownership base.
Doximity differentiates itself in the digital health landscape by combining a vast physician network with robust subscription-based marketing solutions and an expanding portfolio of clinical AI products. Its platform effectively reaches a broad audience across various medical specialties, which is crucial for generating revenue from both pharmaceutical and health-system marketing. Beyond marketing, Doximity also incorporates staffing and telehealth modules that leverage its extensive user base, further solidifying its position in the healthcare technology sector.
Doximity reported fiscal 2027 first-quarter revenue of US$156.6 million for the three months ended June 30, marking a 7% increase from US$145.9 million in the prior-year period. Despite this revenue growth, GAAP net income saw a decline, falling to US$24.3 million from US$53.3 million, resulting in a net margin of 15.5%. Non-GAAP net income and adjusted EBITDA also decreased by 6% to US$55.0 million and US$74.8 million respectively. Operating cash flow dropped by 32% to US$42.0 million. As of the end of the quarter, the company maintained a strong balance sheet with US$273.6 million in cash and US$414.2 million in marketable securities.
Doximity's clinical AI assistant, Doximity Ask, has achieved recognition as the top-performing U.S.-based model on the NOHARM benchmark. The company enhances its offerings with a free, HIPAA-compliant suite that includes Scribe and Dialer. Co-founder and CEO Jeff Tangney highlighted a significant 30% year-over-year growth in workflow active prescribers. Doximity's Fall 2026 investor presentation further notes that AI users account for approximately half of the platform's workflow quarterly active users, with AI Search being a key offering. Moreover, 53% of large U.S. pharmaceutical brands have entered into marketing agreements with the company.
Mid-August saw several firms update their perspectives on Doximity's stock. Needham maintained a Buy rating with a US$41 price target, while Piper Sandler raised its target to US$47. Conversely, Wells Fargo downgraded the stock to Underweight, setting an US$18 target. Other analyst targets range from US$24 to US$40. This divergence in price targets and ratings illustrates a wide spectrum of expectations regarding Doximity's future revenue acceleration and profitability.
For the second quarter ending September 30, Doximity has provided revenue guidance between US$170 million and US$171 million. The full-year fiscal 2027 revenue guidance has been set at US$671 million to US$681 million, with an adjusted EBITDA projection between US$309 million and US$329 million. The company continues to strategically price its marketing solutions based on audience size and the specific mix of modules utilized by clients, consistently reporting strong return-on-investment metrics for both health-system and pharmaceutical customers.
Doximity's ownership structure shows that institutions hold a significant 91.84% of its shares, while management and insiders collectively own 2.81%. The company has 178.25 million shares outstanding, resulting in a market capitalization of approximately US$4.74 billion. Over the past 52 weeks, the stock's trading range has been notably wide, spanning from a low of US$17.15 to a high of US$76.51.
Doximity's fiscal first-quarter revenue growth was primarily driven by subscription revenue from pharmaceutical and health-system marketing, supported by strong net revenue retention rates, including 112% among its top customers. The company measures AI usage growth by tracking a more than 25% quarter-over-quarter increase in AI Search queries and noting that AI users constitute roughly half of its workflow quarterly active users. Doximity identifies an US$18.5 billion total addressable market across its existing segments, with additional billions expected from its new AI Search offering. The platform boasts extensive reach, providing access to over 85% of U.S. physicians across various specialties. As of June 30, Doximity employed 885 people, with over 40% dedicated to research and development. Retail investors should carefully weigh the company's revenue growth against declining GAAP margins and closely monitor the execution and impact of its new AI Search initiatives. The concentrated institutional ownership base may also contribute to increased share-price volatility following quarterly updates.